Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.
https://www.pharmalive.com/wp-content/uploads/2020/11/Viking-Therapeutics’-NASH-Therapy-Shows-Major-Reduction-of-Liver-Fat-and-LDL-Cholesterol-BioSpace-11-19-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-11-19 11:37:442020-11-19 15:00:46Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol